Skip to Main Content

Chapter 29. Parkinson Disease

Mark S. Tinklepaugh, MD

  • Common neurodegenerative disease of the CNS characterized by loss of dopaminergic input in the basal ganglia
  • Cause:
    • Generally considered idiopathic with some evidence of genetic and environmental components
    • Decreased incidence with exposure to cigarette smoking and increased with exposure to pesticides
  • Prevalence and incidence:
    • Affects 1 million people in the United States with approximately 50,000 new cases reported annually
    • Average age of onset is 60
  • Main signs:
    • Resting tremor
    • Rigidity
    • Bradykinesia
    • Festinating gait
    • Postural instability
  • Other signs:
    • Autonomic dysfunction (orthostatic hypotension, GERD, sialorrhea, cramps)
    • Pharyngolaryngeal involvement with aspiration (most common cause of death)
    • Respiratory involvement (chest rigidity, mixed obstructive–restrictive syndrome, decreased response to hypoxemia)
    • Dementia
    • Depression
    • Oculogyric crises
  • Treatment:
    • Goal of treatment: decrease cholinergic activity through anticholinergics or dopamine agonists
    • Levodopa:
      • Levodopa absorbed in proximal small bowel
      • Converted to dopamine by dopa decarboxylase
      • Five to 10% levodopa crosses blood–brain barrier; remainder converted to dopamine peripherally
      • Side effects are N/V, vasoconstriction, hypovolemia, hypotension, decreased myocardial NE stores
      • Levodopa supplementation leads to decreased endogenous production of dopamine
      • Peripheral decarboxylase inhibitor (carbidopa) in combination with levodopa (Sinemet®) decreases peripheral levodopa metabolism which decreases dopamine side effects
      • Entacapone, a COMT inhibitor, used alone (Comtan®) or in combination with carbidopa and levodopa (Stalevo®) to decrease peripheral metabolism of levodopa
      • Amantadine (Symadine®) releases Dopa in the striatum
    • Dopamine agonists:
      • Bind to postsynaptic receptors in the brain
      • Preferred in younger patients since they delay motor complications
      • Side effects include somnolence, insomnia, nausea, hallucinations, and cardiac valvular fibrosis with pergolide (Permax®) and cabergoline (Dostinex®, Cabaser®)
      • Other dopamine agonists include bromocriptine (Parlodel®), pramipexole (Mirapex®), and ropinirole (Requip®)
      • Apomorphine (Apokyn®), another agonist, is the only injectable medication (SQ only, not IV)
    • MAO-B inhibitors:
      • Increase peripheral bioavailability of levodopa. Selegiline (Eldepryl®, Emsam®, Zelapar®) and rasagiline (Azilect®) commonly used
    • Deep brain stimulation (DBS):
      • Used when drug therapy inadequate
      • Pacemaker implanted in brain to stimulate the subthalamic nucleus in the basal ganglia (see chapter 102, Awake craniotomy)

  • Neuro evaluation preoperatively can be useful to establish baseline cognitive ability and to assist in perioperative management
  • Parkinson disease medications and glycopyrrolate (Robinul®) (to decrease sialorrhea and vagal tone) should be administered preoperatively
  • Levodopa half-life short (1–3 hours) and no IV form
  • May consider levodopa via OGT for lengthy non-GI surgery
  • Aspiration and laryngospasm are a significant concern secondary to GERD, sialorrhea, and dysfunction of upper airway musculature
  • Phenothiazines, droperidol, and metoclopramide (Reglan®) are contraindicated as antidopaminergic effect exacerbates extrapyramidal symptoms

  • Regional versus general:
    • Regional anesthesia may be preferred
    • Hypotension secondary to autonomic dysfunction and vasodilatory effect of dopamine agonists is a major concern
    • Regional allows decreased perioperative opioids in patients with increased likelihood (8-fold) of postoperative hallucinations and confusion
  • General anesthesia:
    • Intubation may be difficult due to skeletal muscle rigidity
    • In ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MH Privacy Center Close